Cyclical or Structural

Cyclical or Structural

This chapter puts the report's six pillars on one grid and maps the answer to price. The evidence is genuinely two-sided: an inventory-led, two-market reset that reverses mechanically, set against a US correction now in its third year and discounting that has spread into core brands. The balance tilts cyclical, with a structurally lower ceiling — and at roughly €64 the shares already sit at the structural end of the scenario range, below the partial-recovery case near €87 and the cyclical case near €120.

The two readings on one grid

Every pillar of this report answers the same question two ways. The table below is the report's shared-fact ledger: each row is a number that is not in dispute, read once as a cyclical trough and once as a structural downshift, with the evidence that would settle it. The spine of the report (After the Boom) framed the question; this is where the pieces line up against each other.

Sources: US shipment-vs-sell-out and India per H1 FY26 presentation [1] and the half-year press release [2]; gross margin per FY2025 results [3]; Martell per H1 FY26 presentation [4]; leverage per H1 FY26 results [5]; cash and dividend per FY2025 URD [6].

Two features of the grid matter more than any single row. First, the cyclical and structural readings share the same facts — no row turns on a disputed number, only on interpretation, which is why the debate has stayed unresolved for two years. Second, the deciding evidence in the right-hand column is, in almost every case, a series that will print in a future results statement rather than a judgement to be made now. The report's earlier chapters traced how each line got to where it is; the synthesis is that they will resolve together, and largely on the volume signal that Destock or Demand isolated.

Time, not cash: sizing the cushion

In FY2025 Pernod Ricard paid €1,201m of dividends against €1,133m of reported free cash flow at 3.8x net-debt/EBITDA (Dec 2025), and the €8.4bn inventory cited as the cushion is 84.5% unreleasable aged work-in-progress (€7,077m of €8,371m), so the €4.70 payout is being held less by cash generation than by covenant-light liquidity and a controlling family — Société Paul Ricard, 14.29% of capital / 20.64% of votes — that collects ~€169m of dividends a year and raised its stake through the decline. [7] [8] [9] The cyclical case rests on that balance sheet buying management years to be right (Cash and the Dividend).

Source: H1 FY2026 balance sheet, inventory breakdown at 31 December 2025 — aged work-in-progress is €7,077m of the €8,371m total [10].

That aged work-in-progress is Scotch and cognac laid down years ahead of sale and committed to future vintages [11]; running it down releases cash only by starving the premium supply the whole thesis depends on. The finished-goods and other stock — €1,181m — fell only about €60m over the half [12], so the cushion that funds the dividend through the trough is liquidity and covenant-light debt, not an inventory unlock. It buys time, at a rising cost of debt, rather than a quick reduction in leverage: the cyclical case can be patient, but it cannot self-fund a fast deleveraging.

Three scenarios, mapped to price

The question resolves cleanly onto price because the two readings imply different earnings paths on a multiple that has already compressed below 11x. The framework below reuses the arithmetic from Valuation: a recurring-earnings estimate for each reading, a plausible multiple, and the resulting share price — which lands, in each case, close to where a segment of the sell-side already sits.

Source: derived from FY2024–FY2025 reported recurring EPS [13] and consensus estimates; scenario multiples are illustrative.

Source: current price €63.88 (3 Jul 2026) and derived scenario values; recurring EPS base per FY2025 results [14].

The arithmetic is deliberately plain, and it lands where analysts already are. The structural bar sits on top of the current price: at ~€64 the market is paying for the FY2026 trough as if it were the new base. Partial recovery — the consensus mean near €87 — needs earnings back toward the FY2024 level on today's multiple, no re-rating required. The high case needs both: earnings toward the FY2023 peak and a multiple back to a normal staples 14x. Pernod Ricard trades at ~8.8x trailing recurring earnings and a 7.4% flat-dividend yield, a price that embeds roughly 1% long-run growth against a +3% to +6% mid-term guide — the market is discounting the structural reading, and the sell-side's low target of €62.5 essentially equals the €63.88 quote. [15]

What would settle it

The scenarios do not need to be predicted; they can be watched. Each row below is a line item, where it will appear, and the threshold that would move the read from one column of the grid to the other. None requires access management does not already report.

Sources: US, Travel Retail and price/mix per H1 FY26 results and presentation [16] [17]; gross margin [18]; leverage [19]; FCF and dividend [20].

Of these, the US sell-out line carries the most signal. The report's cyclical case is built on shipments having fallen far faster than the consumer left the shelf (Destock or Demand); were Pernod Ricard's own US sell-out to turn durably negative rather than hold roughly flat, the destock story would convert into a demand story, and several of the other rows — price/mix, gross margin, the FCF gap — would likely follow it into the structural column.

Where the balance sits

The report's central question — whether the decline that began after FY2023 is a cyclical trough or a structural downshift — does not resolve to a single verdict, and the honest synthesis is a tilt, not a call. Most of the fall is inventory and two-market channel effects that mechanically reverse: US shipments running 15 points below a roughly flat consumer, a Martell drag that is one country and one suspended channel, a leverage ratio that rose purely because profit fell. Against that, three facts keep the structural reading alive and cannot be waved away: the US correction has run three years and deepened rather than healed, discounting has spread from adverse geographic mix into the core brands' own price/mix, and even management's recovery guides only to +3% to +6% — a lower cruising speed than the business investors paid for at the peak. Capital allocation offers no tie-breaker either way: the record is disciplined but pro-cyclical (Capital Allocation), so the recovery cash, when it comes, has to be deployed better than the last surplus was.

The evidence, on balance, favours the cyclical read with a structurally lower ceiling, and the price marks where that leaves the shares. At ~€64 the market has already priced the structural end of the scenario range; the partial-recovery case near €87 is roughly +36% from here on earnings recovery alone, no re-rating, while the structural ~€64 case is close to fully discounted. The fact that most threatens the read is the destock's duration; the signal that would settle it first is US sell-out. Both will show up in the results statements to come, which is where this report ends and the monitoring begins.